Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 is involved in cognitive brain function and learning, 98”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [98]
In the citing paper
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85,86,87].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [86]
In the citing paper
“They are involved in multiple biological pathways that could be beneficial in AD including improvement of BBB integrity and vascular health, promotion of homeostasis in microglia and astrocytes, positive effects on adaptative immune cells (including natural killer cells and activated regulatory T cells), improvement of synaptic viability, and neuroprotection [17–26].”
In the citing paper
“Preclinical results in murine models treated with GLP-1RAs suggest that the potential effects of semaglutide in AD may be exerted via impact on several AD-related pathophysiologic processes including neuroinflammatory pathways, vascular and BBB integrity, reduced synaptic loss, and neuroprotection [19, 21, 23–26, 46–48];”
Citations
Cites
Modification of seizure activity by electrical stimulation: II. Motor seizure
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90177-0 · Cited by 7,171
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
The molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Indeed, GLP-1 exerts effects on glucose-dependent insulin secretion, insulin biosynthesis, gastrointestinal motility, islet b-cell neogenesis, energy homeostasis and food intak”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 1×
“Immunohistochemical comparison of the CA3 subregion of the hippocampus using Fluorojade-B, a fluorochrome stain specific for degenerating neuron”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationEnvironmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
Young, D., Lawlor, P. A., Leone, P., Dragunow, M., & During, M. J. (1999) · Nature Medicine · doi:10.1038/7449 · Cited by 732
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citation
Cited by
Items 701–800 of 859
Peptide‐Incorporated Biomaterials Promote Regeneration of Peripheral Nerve Injuries
Zhao, Z., Liu, J., Li, J., Li, D., Ding, J., & Liu, B. (2026) · Advanced Science · doi:10.1002/advs.202524264 · Cited by 8
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
Shi, L.-J., Li, J., Liang, X., He, S., Dou, Y., Peng, J., Cai, W., & Liang, H. (2021) · Fish Physiology and Biochemistry · doi:10.1007/s10695-021-01001-z · Cited by 5
Genetic modifiers of synucleinopathies—lessons from experimental models
Lee, R. M. Q., & Koh, T. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad001 · Cited by 6
Exendin-4 increases the firing activity of hippocampal CA1 neurons through TRPC4/5 channels
Sun, H.-Z., Shen, F.-S., Li, X.-X., Liu, C., Xue, Y., Han, X., Chen, X., & Chen, L. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.08.001 · Cited by 4
A sympathetic brake on gut GLP-1 release
López-Gambero, A. J., Jouque, V., & Cota, D. (2024) · Neuron · doi:10.1016/j.neuron.2024.02.015 · Cited by 4
PEPTIDE DELIVERY VIA NASAL ROUTE: EXPLORING RECENT DEVELOPMENTS AND APPROACHES
PALDE, C., Barot, T., Chakraborthy, G. S., & PATEL, L. D. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i4.50626 · Cited by 4
Romano, A. D., Villani, R., Sangineto, M., Cassano, T., & Serviddio, G. (2022) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n474 · Cited by 5
Park, S.-H., & Kim, D. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.160078 · Cited by 4
Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Beltrán, D. O., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.09.004 · Cited by 5
Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis
Drucker, D. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50009-x · Cited by 5
Self-citationRole of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling
Bavec, A., Jiang, Y. Z., Langel, Ü., & Zorko, M. (2006) · Molecular Biology Reports · doi:10.1007/s11033-006-9015-9 · Cited by 4
Richard, J. E., Mohammad, A., Go, K. A., McGovern, A. J., Rechlin, R. K., Splinter, T. F. L., Lieblich, S. E., Radovic, L. K., Feng, L., Blankers, S. A., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106088 · Cited by 4
Unravelling the novel insights between miR-7 and Parkinson’s disease (PD)
Kushwaha, S., Lakhanpal, V., Elangovan, A., Iyer, M., Kinoshita, M., Narayanasamy, A., HariKrishnaReddy, D., Siama, Z., Yadav, M. K., & Vellingiri, B. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08834-7 · Cited by 4
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer’s Disease
Dash, D., Bairy, L. K., & Chogtu, B. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2462 · Cited by 3
Physical Activity and Dietary Interventions for Mental Health in Ageing and Longevity
Lakhman, S. S., Murzello, A., & Gueits, P. G. (2024) · Healthy ageing and longevity · doi:10.1007/978-3-031-68513-2_5 · Cited by 5
Gut Hormones: Possible Mediators of Addictive Disorders?
Nestor, L. J., & Ersche, K. D. (2024) · European Addiction Research · doi:10.1159/000540743 · Cited by 5
Siervo, M., Johnston, F., Calton, E. K., James, A. P., Stephan, B. C. M., Hornsby, A. K. E., Davies, J. S., & Burn, D. J. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.10.167 · Cited by 3
Sharma, P. K., Yadav, M., & Mehta, N. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0755 · Cited by 3
Андреевна, Л. Е., Shevelyova, M. P., Андреевна, В. А., Deryusheva, E. I., Chaplygina, A. V., Rastrygina, V. A., Валериевич, М. А., Alikova, V. D., Nazipova, A. A., Permyakova, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094095 · Cited by 3
Exendin-4 effects on islet volume and number in the mouse pancreas
Khorsandi, L., & Nejaddehbashi, F. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_098 · Cited by 3
Elsaeed, E. M., Hamad, A., Erfan, O. S., El-Shahat, M. A., & Ebrahim, F. (2022) · Egyptian Academic Journal of Biological Sciences. D, Histology and Histochemistry · doi:10.21608/eajbsd.2022.214866 · Cited by 4
Cao, T., Wang, L., Jiao, S., Chen, H., Lin, C., Zhang, B., & Cai, H. (2023) · Neuropsychobiology · doi:10.1159/000533148 · Cited by 3
Piątkowska‐Chmiel, I., Gawrońska‐Grzywacz, M., Pawłowski, K., Dudka, J., Ślaska, B., Tkaczyk‐Wlizło, A., Kowal, K., & Herbet, M. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240517094428 · Cited by 3
Trophic Factors in the Therapeutic Challenge Against ALS: Current Research Directions
Sobuś, A., & Machaliński, B. (2016) · InTech eBooks · doi:10.5772/63428 · Cited by 5
Deželak, M., & Bavec, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.033 · Cited by 3
Yuan, J., Guo, J., ZHANG, M., Wang, Q., Huang, H., & Chen, Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3065 · Cited by 3
Lumeng, J. C. (2013) · Academic Pediatrics · doi:10.1016/j.acap.2012.10.008 · Cited by 3
Molecular Mechanisms of Geniposide and Genipin Against Alzheimer’s Disease
Liu, J., Yin, F., Guo, L., Zhang, J., & Zidichouski, J. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411462-3.00024-2 · Cited by 6
Lietzau, G., Ntika, S., Pintana, H., Tracy, L. M., Klein, T., Nyström, T., Darsalia, V., Patrone, C., & Krizhanovskii, C. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01079-2 · Cited by 3
Jo, D., Ahn, S. Y., Choi, S. Y., Choi, Y., Lee, D. H., & Song, J. (2024) · Clinical Nutrition Research · doi:10.7762/cnr.2024.13.2.121 · Cited by 2
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Zohora, F. T., Mou, S. S., Haque, M. R., Baidya, M., Jahan, I., & Al-Mamun, M. E. (2025) · Translational Medicine of Aging · doi:10.1016/j.tma.2025.08.005 · Cited by 2
In vivo functional profiling and structural characterization of the human GLP1R A316T variant
Eid, L. E., Manchanda, Y., Austin, G. O., Deane-Alder, K., Rujan, R., Mariam, Z., Oqua, A. I., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., et al. (2026) · Science Advances · doi:10.1126/sciadv.adw0899 · Cited by 9
Juthi, S. S., Ansari, P., Ahmed, M. F., Khan, J. T., Seidel, V., Kumar, S., Kumari, R., McKillop, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798309 · Cited by 2
Bashaw, A. G., Roman-Ortiz, C., Gao, S. X., Schier, L. A., Borner, T., & Kanoski, S. E. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.006 · Cited by 5
Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer’s Disease
Day, S. M., & Ma, T. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00355-y · Cited by 3
Altıntaş, F., Çalışkan, S., Tunç-Ata, M., Kılıç-Toprak, E., Tokgün, O., Avci, N. E., & Küçükatay, V. (2023) · PubMed Central · doi:10.22038/ijbms.2023.70711.15369 · Cited by 2
“Current and emerging drug therapies in Alzheimer’s disease: A pathophysiological Perspective”
Aparajita, A., Jain, U., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.078 · Cited by 2
Astrocytes of the hippocampus and responses to periprandial neuroendocrine hormones
Loera‐Lopez, A. L., Lord, M. N., & Noble, E. E. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.114913 · Cited by 2
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Design and Optimization of Expression Cassettes Including Promoter Choice and Regulatory Elements
Fitzsimons, H. L., & During, M. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50002-2 · Cited by 2
Self-citationYarnall, A. J. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.7 · Cited by 2
Coming of Age for the Incretins
Holst, J. J., & Deacon, C. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-572-5_14 · Cited by 2
Swain, T. R., Swain, M., & Pattanaik, S. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20172242 · Cited by 3
Couch Potato: The Antithesis of Hormesis
Mattson, M. P., Stranahan, A. M., & Martin, B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-495-1_8 · Cited by 2
GÓRSKA, A., & Arciszewski, M. B. (2020) · Medycyna Weterynaryjna · doi:10.21521/mw.6374 · Cited by 3
Hunt, K. F., Cheah, Y. S., & Amiel, S. A. (2011) · Wiley eBooks · doi:10.1002/9781444347319.ch9 · Cited by 2
Non‐Insulin Parenteral Therapies
Holst, J. J., Madsbad, S., & Schmitz, O. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch30 · Cited by 4
Ghosh, K., & Sobhia, M. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1721735/v1 · Cited by 2
GLP-1R agonists activate human hypothalamic neuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Seah, E., Chen, J., Jawahar, B., Alcaino, C., Macarelli, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.587825 · Cited by 4
In vivo functional profiling and structural characterisation of the human Glp1r A316T variantPreprint
Eid, L. E., Deane-Alder, K., Rujan, R., Mariam, Z., Oqua, A. I., Manchanda, Y., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., Rutter, G. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.19.619191 · Cited by 2
Exercise and the Brain–Gut Axis
Godinho, D. B., Fighera, M. R., & Royes, L. F. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99971-7.00019-9 · Cited by 1
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Qi, L., Lin, L., Zheng, J., Liu, X., Liu, X., Chen, Z., & Liu, L. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf265 · Cited by 1
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 3
Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice
Xiang, Y., Yan, X., Li, R.-R., Li, C., Yin, D., Luo, C.-C., Xiong, Y.-Q., Hong, Y., Li, Y.-X., & Xia, B.-J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343995 · Cited by 1
Fu, X., Xie, Y., Xie, Y., Han, A., Zhou, X., Zhang, S., Shen, C., Zhang, Y., Wang, L., & Xie, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1860661 · Cited by 1
Glucagon like-peptide-1 receptor is covalently modified by endogenous mono-ADP-ribosyltransferase
Deželak, M., & Bavec, A. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1225-0 · Cited by 1
The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study
Ghanizada, H., Christensen, R. H., Al‐Karagholi, M. A., Elbahi, F. A., Coskun, H., & Ashina, M. (2022) · Peptides · doi:10.1016/j.peptides.2022.170736 · Cited by 1
Antiepileptic effects of exenatide in penicillin induced acute epilepsy model in rats
Yildiz, A., Kocacan, S. E., & Him, A. (2023) · Indian Journal of Experimental Biology · doi:10.56042/ijeb.v61i06.1931 · Cited by 2
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Modulation of respiration and hypothalamus
Fukushi, I., Yokota, S., Hasebe, Y., Pokorski, M., & Okada, Y. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.06.006 · Cited by 2
Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect
Wang, X., Chen, L., Li, W., He, Z., & Hai-ying, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241304673 · Cited by 1
Zoicas, I., & Kornhuber, J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110656 · Cited by 3
Kong, X., Yang, Y., Li, H., Cui, W., Wu, X., Gong, M., & Li, Y. (2021) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10202-2 · Cited by 1
Incretin physiology in health and disease
Meier, J. J., & Nauck, M. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch11 · Cited by 1
Gut-Brain Communications: Not the Same at All Ages
Banks, W. A. (2010) · Endocrinology · doi:10.1210/en.2009-1442 · Cited by 1
Self-citationSesti, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01072.x · Cited by 1
The elusive pathways behind montelukast's repurposing for Alzheimer's diseasePreprint
Marques, C. F., Marques, M. M., & Justino, G. C. (2022) · doi:10.22541/au.166678108.88018118/v1
Cerroni, C., Steiner, A., Seanez, L., Kwon, S.-H., & Lewis, A. S. (2023) · bioRxiv · doi:10.1101/2023.04.21.537724
Semaglutide Attenuates Neuroinflammation in MicePreprint
Belmont-Rausch, D. M., Ludwig, M. Q., Bentsen, M. A., Hansen, S. N., Secher, A., Holst, D., Moreno, J., Das, V., Egerod, K. L., Bjerregaard, A.-M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.10.698763 · Cited by 1
The binding and activation of the glucagon-like peptide-1 receptor by exendin-4
Nasr, E. M. N. (2010) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Hölscher, C. (2012) · Wiley eBooks · doi:10.1002/9781118185537.ch10 · Cited by 1
The activation of the glucagon-like peptide-1 (GLP-1) receptor by peptide and non-peptide ligands
Wishart, C. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
GLP-1 REGULATES PROLIFERATION OF GLP-1 SECRETING CELLS THROUGH A FEEDBACK MECHANISM
Mohamed, M. A. (2010)
Cukierman‐Yaffe, T. (2013) · Diabetes Management · doi:10.2217/dmt.13.60 · Cited by 1
GLP-1 et système nerveux : un mécanisme de son action antidiabétique
Burcelin, R., Massebœuf, M., & Cabou, C. (2008) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(08)74894-6
New therapeutic strategy for Alzheimer's disease using antidiabetes agents
Yokono, K. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12031
Rasouli, M., Abbasi, S., Sarsaifi, K., Hani, H., Ahmad, Z., & Omar, A. R. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0514-6
Dedov, I. I., & Shestakova, M. V. (2008) · Diabetes Mellitus · doi:10.14341/2072-0351-5594
Pleiotropic Effects of an Incretin Hormone
Oh, S. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.120
Andréasson, S. (2015) · Epsilon Archive for Student Projects (Swedish University of Agricultural Sciences)
GABA A receptor-mediated synaptic and tonic currents in rat
Korol, S. V., Jin, Z., Babateen, O., & Birnir, B. (2014)
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease
Mohd, S., Shaikh, S., Waseem, S. M. A., Shaki, S., Abuzenadah, A. M., Biswas, D., Tabrez, S., Ashraf, G. M., & Kamal, M. A. (2015) · EXCLI journal · doi:10.17179/excli2015-252 · Cited by 33
Felice, F. G. D., & Ferreira, S. T. (2014)
A VAPB e a Esclerose Lateral Amiotrófica
Beccari, M. S. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.41.2016.tde-18012016-155440 · Cited by 1
Coatti, G. C. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2016.tde-14012016-143346
DPP 4 (dipeptidylpeptidase-4) inhibitors: beyond glycemic control
Gothwal, S. (2013) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-033108185
GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator
Babateen, O. (2016) · Uppsala University Publications (Uppsala University) · Cited by 1
Exenatide as a novel treatment for Parkinson's Disease
Avilés-Olmos, I. (2013) · UCL Discovery (University College London)
Metabolic Actions of Glucagon-Like Peptides
Wideman, R. D., & Kieffer, T. J. (2005) · Oxidative stress and disease · doi:10.1201/9781420028362.ch19
Incretins, Incretinmimetics, Inhibitors (2 nd part)
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders
Fedele, E. (2016) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.1000e151
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and
McGrath, N., Glastras, S. J., HOCKING, S. L., Tjoeng, I., Krause, M., Fulcher, G. R., & McGrath, R. T. (2015)
Metadata
- Authors
- During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., & Haile, C. N.
- Affiliations
- University of Auckland (NZ)
- Thomas Jefferson University (US)
- St. Louis VA Medical Center (US)
- University of Toronto (CA)
- Corresponding author
- During, Matthew J
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-08-17
- Volume
- 9
- Issue
- 9
- Pages
- 1173-1179
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2124852816
- Cited by
- 851
- References
- 42
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 50 · 2023: 39 · 2022: 58 · 2021: 53 · 2020: 44 · 2019: 36 · 2018: 37 · 2017: 39 · 2016: 34 · 2015: 54 · 2014: 46 · 2013: 47 · 2012: 43
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Marsden Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, associative learning, spatial learning, memory, hippocampus, neuroprotection, kainate-induced seizures, neuronal apoptosis, cognitive enhancement, gut-brain signaling
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Administration, Intranasal, Amino Acid Sequence, Animals, Behavior, Animal, Cognition, Glucagon, Hippocampus, Kainic Acid, Learning, Male, Molecular Sequence Data, Neurons, Peptide Fragments, Protein Precursors, Seizures, Signal Transduction, Gene Expression, Rats, Sprague-Dawley, Apoptosis, Sequence Homology, Amino Acid, Gene Transfer Techniques, Receptors, Glucagon, Mice, Knockout, Neuroprotective Agents, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.